Sun Pharma stock falls 1.60 percent as company funds dermatology

Published on 10/07/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sun Pharma stock traded at INR 1,775.30 on October 7, 2026, while Q1 FY27 revenue reached INR 15,300 crore, up 11.9 percent. Net profit rose 26.4 percent.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (ISIN INE044A01036) was trading at INR 1,775.30 on the NSE at 2:05 p.m. IST on October 7, 2026, down 1.60 percent from the previous close. The company had announced a $2.5 million dermatology professorship at Mount Sinai on October 6, giving the stock a fresh corporate event alongside its current market move.

A $2.5 million dermatology commitment

According to PR Newswire on October 6, 2026, Sun Pharmaceutical Industries established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai. The endowment will fund academic leadership, research, education and mentorship, with Mark G. Lebwohl installed as the inaugural professor.

The announcement reinforces Sun Pharma's dermatology positioning, but it does not carry disclosed sales guidance or financial terms. The company's larger pipeline move came on September 28, 2026, when it secured exclusive rights outside the United States and China to commercialize and manufacture lerodalcibep, a once-monthly cholesterol treatment.

Business Standard reported that the agreement gives Sun Pharma access to a $3.7 billion PCSK9 inhibitor market. The companies did not disclose the upfront payment, milestones or royalty rates.

Q1 revenue rises 11.9 percent

Sun Pharma's operating picture remains the stronger numerical anchor. In Q1 FY27, revenue increased 11.9 percent year over year to INR 15,300 crore, while net profit rose 26.4 percent to INR 2,910.80 crore, according to Univest in its October 6, 2026 review. Operating margin reached 32.52 percent in the quarter, compared with 28.64 percent a year earlier.

That combination of double-digit revenue growth and faster profit growth gives investors a clearer benchmark than the Mount Sinai announcement. It also keeps attention on whether innovative medicines and specialty products can sustain the company's margin profile.

Valuation and yearly range

Sun Pharma's market capitalization stood at INR 4.3 trillion on October 7, 2026. Its NSE 52-week range was INR 1,583.70 to INR 2,046.90, leaving the intraday price below the yearly high while the stock remained above its yearly low.

At the October 5, 2026 close, Sun Pharma carried a P/E of 35.29 against an industry P/E of 37.53, according to Univest. The 2.24-point valuation gap means the stock was priced below the sector multiple even as Q1 profit growth outpaced revenue growth.

Sun Pharma stock trades below its high

Sun Pharma stock was last at INR 1,775.30 on the NSE on October 7, 2026 at 2:05 p.m. IST, with volume of 659,489 shares and a daily change of -1.60 percent.